Early-stage investment in immuno oncology: riding the waves of hope & hype

Published: 15 March 2022
Viewpoint
W Joost Lesterhuis,
Helga Mikkelsen,
Jonathan Tobin,
Michael Bettess

Immuno-oncology has its fundamental origins in translating academic research through venture capital and public market investment. Pioneer company Medarex is a classic
example, which brought the first wave of key checkpoint inhibitor drugs to market. Since then, the Immuno-oncology field has grown at an exponential rate.

Read now